Study Design Location Population Intervention arms RR (95% CI) ARR
iPrEx Phase III, safety and efficacy Brazil, Ecuador, Peru, South Africa, Thailand, United States 2499 MSM Daily oral TDF-FTC 44% (15,63) 2.2%
TDF2 Phase III, safety and efficacy Botswana 1219 heterosexual men and women Daily oral TDF-FTC 75% (55,87) 2.5%
Partners rEP Phase III,  safety and efficacy Kenya, Uganda 4758 serodiscordant heterosexual couples Daily oral TDF; Daily oral TDF-FTC 62% (22,83) 2.4%
FEM-PrEP Phase III, safety and effectiveness Kenya, Tanzania, South Africa 2120 heterosexual women Daily oral TDF 6% (-52,41) 0.2%
RR: Relative Risk; ARR: Absolute Risk Reduction; MSM: Men Who have Sex with Men; TDF-FTC: Tenofovir-Emtricitabine; TDF: Tenofovir disoproxil fumarate
Table 1: Clinical trial design and results from published PrEP studies.